Grant name: Imaging, Biomarkers and Digital Pathomics for the Early Detection of Premetastatic Cancer and Precancerous Lesions Associated with Lethal Phenotypes
Funding organization: National Institutes of Health (NIH), National Cancer Institute (NCI)
Total funding amount: Not specified
Duration: Maximum project period of 5 years
Primary objective: To support projects that improve early detection of aggressive cancers and precancerous lesions.
Key stakeholders: Researchers, healthcare providers, and patients.
Funding source and type: NIH Research Project Grant (R01)
Significance: Addresses critical clinical needs in cancer detection.
Grant frequency: Recurring.
Higher Education Institutions
Public/State Controlled Institutions of Higher Education
Private Institutions of Higher Education
Nonprofits Other Than Institutions of Higher Education
For-Profit Organizations
Small Businesses
Local Governments
State Governments
County Governments
City or Township Governments
Indian/Native American Tribal Governments (Federally Recognized)
Foreign Institutions
Organizations must have established preliminary data to support their methodologies.
Individuals from underrepresented racial and ethnic groups as well as individuals with disabilities are encouraged to apply.
Integration of imaging, biomarkers, and digital pathomics.
Early detection of organ confined premetastatic aggressive cancer.
Identification of precancerous lesions associated with lethal phenotypes.
Improved diagnostic performance.
Reduced overdiagnosis and false positives.
Expertise in imaging, biomarkers, pathomics, and other -omic methodologies.
Ability to integrate various data sources for clinical application.
Application budgets are not limited but must reflect actual project needs.
Applications are accepted until September 8, 2025.
Must comply with NIH Grants Policy Statement.
Follow the SF424 (R&R) Application Guide for submission.
Encourages multidisciplinary collaboration among imaging and biomarker research communities.
Reissue of PAR-19-264.